



Cholinergic System Neurodegeneration: Novel Pharmacotherapy

Guest Editors:

Prof. Dr. Javier del Pino

Departamento de Farmacología
y Toxicología, Universidad
Complutense de Madrid, 28040
Madrid, Spain

Prof. Dr. Paula Moyano

Departamento de Farmacología
y Toxicología, Universidad
Complutense de Madrid, 28040
Madrid, Spain

Deadline for manuscript
submissions:

31 December 2024

Message from the Guest Editors

This Special Issue, entitled “Cholinergic System Neurodegeneration: Novel therapies”, will mainly focus on the molecular, structural, neurochemical, pathological, and behavioral studies of the cholinergic system’s neurodegeneration, its impact on disease, and novel therapies used to avoid them.

Acetylcholine was the first neurotransmitter identified by the studies of Henry Dale and Otto Loewi in 1936, which discovered chemical neurotransmission and afterwards the complex regulation of the cholinergic system and its functions. Cholinergic transmission regulates many functions peripherally (cardiovascular, gastrointestinal, respiratory, and reproductive systems, among others) and on the central nervous system (affective, memory, learning, and sleep regulation, among others), and its disruption is involved in different harmful neuropathologies.

As Guest Editor, I would be very pleased if you contributed to this Special Issue with either an original research paper or a focused review with emphasis on cholinergic system neurodegeneration and potential therapeutic approaches.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)